Conestoga Capital Advisors LLC grew its stake in shares of Simulations Plus, Inc. (NASDAQ:SLP - Free Report) by 17.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,609,388 shares of the technology company's stock after purchasing an additional 383,126 shares during the quarter. Conestoga Capital Advisors LLC owned approximately 12.97% of Simulations Plus worth $63,982,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Ameriprise Financial Inc. boosted its stake in Simulations Plus by 16.7% during the 4th quarter. Ameriprise Financial Inc. now owns 607,902 shares of the technology company's stock valued at $16,954,000 after purchasing an additional 86,868 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Simulations Plus by 7,753.3% during the fourth quarter. Janus Henderson Group PLC now owns 542,899 shares of the technology company's stock valued at $15,141,000 after buying an additional 535,986 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Simulations Plus by 6.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 419,241 shares of the technology company's stock worth $11,693,000 after buying an additional 24,266 shares during the period. Royce & Associates LP grew its holdings in Simulations Plus by 56.6% in the 4th quarter. Royce & Associates LP now owns 371,797 shares of the technology company's stock worth $10,369,000 after buying an additional 134,381 shares in the last quarter. Finally, Kennedy Capital Management LLC grew its holdings in Simulations Plus by 59.4% in the 4th quarter. Kennedy Capital Management LLC now owns 289,286 shares of the technology company's stock worth $8,068,000 after buying an additional 107,766 shares in the last quarter. 78.08% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several analysts have weighed in on SLP shares. William Blair reaffirmed an "outperform" rating on shares of Simulations Plus in a research note on Tuesday, June 3rd. KeyCorp lifted their price objective on shares of Simulations Plus from $32.00 to $40.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. Wall Street Zen upgraded shares of Simulations Plus from a "sell" rating to a "hold" rating in a research report on Monday, April 28th. Finally, Craig Hallum lowered their target price on shares of Simulations Plus from $45.00 to $36.00 and set a "buy" rating on the stock in a research note on Friday. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Simulations Plus has an average rating of "Moderate Buy" and a consensus target price of $41.25.
View Our Latest Research Report on Simulations Plus
Simulations Plus Trading Down 0.6%
Shares of Simulations Plus stock opened at $18.95 on Tuesday. Simulations Plus, Inc. has a 52 week low of $18.66 and a 52 week high of $49.71. The stock has a market cap of $381.10 million, a PE ratio of 47.38 and a beta of 0.97. The company's 50-day moving average price is $30.64 and its two-hundred day moving average price is $30.12.
Simulations Plus (NASDAQ:SLP - Get Free Report) last released its earnings results on Thursday, April 3rd. The technology company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of $0.25 by $0.06. The business had revenue of $22.43 million for the quarter, compared to the consensus estimate of $21.93 million. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The business's revenue for the quarter was up 22.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.20 EPS. On average, equities analysts predict that Simulations Plus, Inc. will post 1.09 EPS for the current fiscal year.
Insider Activity
In other news, Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $33.51, for a total transaction of $670,200.00. Following the sale, the director now owns 3,344,157 shares in the company, valued at $112,062,701.07. The trade was a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 19.40% of the company's stock.
About Simulations Plus
(
Free Report)
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Simulations Plus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Simulations Plus wasn't on the list.
While Simulations Plus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.